EndoTODAY | EndoATLAS | OPD

Parasite | Eso | Sto | Cancer | ESD

Boxim | DEX | Sono | Schedule

Home | Recent | Blog | Links

EndoTODAY ³»½Ã°æ ±³½Ç


[°ÇÁø À§³»½Ã°æÀ» ¸î ¼¼¿¡ Áß´ÜÇÒ °ÍÀΰ¡?] - ðû

1. ¸î ¼¼±îÁö °ËÁø ³»½Ã°æÀ» ¹Þ¾Æ¾ß Çϴ°¡?

2. À§¾Ï °ËÁø ±Ç°í¾È¿¡ ¾ð±ÞµÈ °ËÁø À§³»½Ã°æ ¿¬·É »óÇѼ±

3. ´ëÀå¾Ï °ËÁø Áß´Ü ½ÃÁ¡ - Â÷Àç¸í ±³¼ö´ÔÀÇ ¸®ºä

4. °ËÁøÀÇ bias¿Í °ËÁø ³»½Ã°æ ¿¬·É»óÇѼ±¿¡ ´ëÇÑ °íÂû

5. Cases

6. FAQ

7. References

2021³â ±â´ë¿©¸íÇ¥


1. µé¾î°¡´Â ¸». ¸î ¼¼±îÁö °ËÁø ³»½Ã°æÀ» ¹Þ¾Æ¾ß Çϴ°¡?

2021³â ±â´ë¿©¸íÇ¥. ±Ù°Å´Â ¾øÁö¸¸ ±â´ë ¿©¸íÀÌ 10³â ÀÌ»óÀÏ ¶§ °ËÁøÀ» ÇÑ´Ù´Â °ÍÀÌ ÀÇ·á°èÀÇ ÁöÇýÀÔ´Ï´Ù.

[2014-10-7. ¾Öµ¶ÀÚ Áú¹®]

¾È³çÇϼ¼¿ä. °ËÁø¼¾ÅÍ¿¡¼­ ÀÏÇÏ´Â ¼ÒÈ­±â ³»°ú ÀÇ»çÀÔ´Ï´Ù. Æò¼Ò µµ¿òÀ» ¸¹ÀÌ ¹Þ°í ÀÖ½À´Ï´Ù. Áú¹®ÀÌ ÀÖ¾î ¸ÞÀÏÀ» µå¸³´Ï´Ù. °ËÁø À§³»½Ã°æÀ» ¾ðÁ¦±îÁö ÇØ¾ß ÇÏ´ÂÁö ±Ã±ÝÇÕ´Ï´Ù. ´Ù¸¥ °÷Àº º¸Åë 80¼¼ ÀÌ»óÀº Á¶¿µ¼úÀ» ±ÇÇϴµ¥ ±Ù°Å°¡ ÀÖ´Â °ÍÀÎÁö. ¾Æ´Ï¸é °Ç°­»óÅ°¡ ±¦ÂúÀ¸¸é °è¼Ó °ËÁø ³»½Ã°æÀ» ÇØ¾ß ÇÏ´ÂÁö ±Ã±ÝÇÕ´Ï´Ù.


[2014-10-10. ÀÌÁØÇà ´äº¯]

¸Å¿ì Áß¿äÇÑ Áú¹®ÀÔ´Ï´Ù. ´äº¯Àº ½±Áö ¾Ê½À´Ï´Ù. ÀÇÇÐÀû À̽´¿Í »çȸÀû À̽´°¡ ¼¯¿©Àֱ⠶§¹®ÀÔ´Ï´Ù. ÀÏ´Ü ½ÃÀÛÇÑ ÀÏÀ» ¹°¸®±â ¾î·Æ´Ù´Â Á¡µµ ÀÖ½À´Ï´Ù. Âü °ï¶õÇÑ ÀÏÀÔ´Ï´Ù.

´ëÀå³»½Ã°æ ºÐ¾ß¿¡¼­ ¾î¶»°Ô µ¹¾Æ°¡°í ÀÖ´ÂÁö Âü°íÇϸé ÁÁÀ» °Í °°½À´Ï´Ù. ¹Ì±¹ÀÇ °æ¿ìÀÔ´Ï´Ù. ¹Ì±¹¿¡¼­µµ 2000³â´ë ÃʹݱîÁö´Â °í·ÉÀÚ¿¡¼­ ´ëÀå³»½Ã°æÀÇ yield°¡ ÁÙ¾îµéÁö ¾ÊÀ¸¹Ç·Î ³ªÀ̶§¹®¿¡ Áß´ÜÇÏÁö´Â ¸»ÀÚ´Â ³í¹®ÀÌ ¹ßÇ¥µÇ±âµµ ÇÏ¿´½À´Ï´Ù.

±×·¯³ª ¹Ý´ë ÀÚ·áµµ ¸¹¾Ò½À´Ï´Ù. ½Ê¿©³â°£ÀÇ ³í¶õ ³¡¿¡ °á±¹ ±¹°¡Â÷¿øÀÇ °¡À̵å¶óÀÎÀÌ ¸¸µé¾îÁ® USPSTF¸¦ ÅëÇÏ¿© Á¤¸®µÇ°í ¹ßÇ¥µÇ¾ú½À´Ï´Ù (¹Ì±¹¿¡¼­ ¿¹¹æ¿¡ °üÇÑ ¸ðµç °¡À̵å¶óÀÎÀº US Preventive Service Task Force¸¦ ÅëÇÏ¿© Á¤¸®µÇ°í ÀÖ½À´Ï´Ù). 2008³â ¹ßÇ¥µÈ USPSTF °¡À̵å¶óÀÎÀÌ ÇöÀçÀÇ ´ëÀå¾Ï screening Ç¥ÁØÀ̸ç 2015³â¿¡ °³Á¤µÉ °ÍÀ̶ó°í ÇÕ´Ï´Ù. 75¼¼°¡ µÇ¸é routine colon cancer screeningÀ» ±ÇÇÏÁö ¾ÊÀ¸¸ç individualize Ç϶ó´Â °ÍÀÔ´Ï´Ù. ´ëÀå¾Ï °íÀ§Çè ȯÀÚ¿¡¼­¸¸ Ç϶ó´Â ¶æÀ¸·Î Çؼ®ÇÏ¸é µË´Ï´Ù. 85¼¼°¡ µÇ¸é individualize ÇÒ °Íµµ ¾øÀÌ ±×³É ÇÏÁö ¸»¶ó´Â °ÍÀÔ´Ï´Ù.

@ Adults age 76 to 85 years: The USPSTF recommends against routine screening for colorectal cancer in adults 76 to 85 years of age. There may be considerations that support colorectal cancer screening in an individual patient.

@ Adults older than age 85 years: The USPSTF recommends against screening for colorectal cancer in adults older than age 85 years.

Èï¹Ì·Î¿î °ÍÀº USPSTF °¡À̵å¶óÀÎÀÌ ½ÅÁÖ´ÜÁöó·³ ¸ð¼ÅÁø´Ù´Â Á¡ÀÔ´Ï´Ù. ƯÈ÷ ºñÀÇ·áÀο¡°Ô´Â ¸ðµç ä³ÎÀ» ÅëÇÏ¿© ÀÏ°üµÈ Á¤º¸°¡ Á¦°øµÇ°í ÀÖ½À´Ï´Ù. Áï USPSTF °¡À̵å¶óÀο¡ µû¸¥ ÅëÀÏµÈ Á¤º¸°¡ Á¦°øµÇ°í ÀÖ½À´Ï´Ù. ÇÐÀÚµéÀº »õ·Î¿î µ¥ÀÌŸ·Î »õ·Î¿î ÁÖÀåÀ» Çϱ⵵ ÇÕ´Ï´Ù. Çа迡¼­´Â ¿©·¯ ÀÇ°ß¿¡ ´ëÇÑ Åä·ÐÀÌ ÇÊ¿äÇÕ´Ï´Ù. ±×·¯³ª Á¤Ã¥ ÀÔ¾ÈÀ̳ª ÀϹÝÀο¡ ´ëÇÑ ¼³¸í¿¡¼­´Â ÅëÀÏµÈ ¸ñ¼Ò¸®°¡ Áß¿äÇÕ´Ï´Ù. Çа迡¼­ °ËÁõµÇÁö ¾ÊÀº ¼³ÀÍÀº ÁÖÀåÀ» ±¹¹Îµé¿¡°Ô ÇÏ¸é ¾È µË´Ï´Ù. ³ª»Û ÀÏÀÔ´Ï´Ù.

¹Ì±¹ ´ëÀå³»½Ã°æ °¡À̵å¶óÀΰú ±× È°¿ë ½ÇÅ¿¡´Â ºÐ¸íÈ÷ ¹è¿ï Á¡ÀÌ ÀÖ½À´Ï´Ù. ÇÑ ¿¹·Î New York Times ±â»ç¿Í Mayo ClinicÀÇ ÀÎÅÍ³Ý È¯ÀÚ»ó´ãÀ» ¼Ò°³ÇÕ´Ï´Ù. USPSTF °¡À̵å¶óÀÎÀÌ Ãæ½ÇÇÏ°Ô ¹Ý¿µµÈ ³»¿ëÀÔ´Ï´Ù.

¸ÕÀú New York Times ±â»çÀÔ´Ï´Ù. °í·ÉÀÚ¿¡¼­ ´ëÀå³»½Ã°æÀÌ ³Ê¹« ¸¹ÀÌ ½ÃÇàµÇ°í ÀÖ´Ù°í Çϳ׿ä.

"Why not screen everyone? Because, he explained, at older ages the benefits diminish. ¡°It¡¯s difficult to have this conversation, to say, ¡®You don¡¯t need this because you¡¯re not going to live long enough to benefit,¡¯¡± he acknowledged. But colon cancer develops slowly, and in the many years it takes for small polyps to evolve into cancer, if they do, most old people will have died of other diseases."

Mayo clinicÀÇ È¯ÀÚ»ó´ãÄÚ³ÊÀÔ´Ï´Ù.

"People older than age 75 who have been getting regular colon cancer screening since age 50 and who have had consistently negative screenings - no polyps (adenomas) or colon cancer - and are not at an increased risk of colon cancer because of family history need not continue getting routine screening. That's according to colon cancer screening guidelines issued by the U.S. Preventive Services Task Force (USPSTF) and the American College of Physicians (ACP).

The upper age limit was set after studies determined that the net benefit of screening after age 75 was small. However, the USPSTF guidelines do recommend colon cancer surveillance for people older than age 75 who have an increased risk of colon cancer, such as family history, a previously diagnosed colon cancer or adenomatous polyps.

The American Cancer Society and the American College of Gastroenterology don't specify an upper age limit beyond which colon cancer screening is no longer recommended.

The USPSTF and ACP recommend that colon cancer screening be done using high-sensitivity fecal occult blood testing (FOBT), sigmoidoscopy with FOBT or colonoscopy."

´Ù½Ã À§¾ÏÀ¸·Î µ¹¾Æ°¡ °õ°õÈ÷ »ý°¢Çغ¾´Ï´Ù. À§¾Ï °ËÁø ³»½Ã°æÀº ¸î ¼¼¿¡ ½ÃÀÛÇÏ¿© ¸î ¼¼¿¡ ³¡³»´Â °ÍÀÌ ÁÁÀ»±î¿ä? ¾Æ½±°Ôµµ °øÀÎµÈ °¡À̵å¶óÀÎÀº ¾ø½À´Ï´Ù. ¿¬±¸°á°úµµ ºÎÁ·ÇÕ´Ï´Ù. ÀϺ»¿¡¼­µµ ÁÁÀº ÀÚ·á´Â ¾ø°í Á¾¼³ ºñ½ÁÇÑ º¸°í¼­¹Û¿¡ ¾ø´Ù°í ÇÕ´Ï´Ù (¸µÅ©). ÀÚ·á°¡ ¾øÀ¸´Ï À§¾ÏÀ» ¸¹ÀÌ º¸´Â ÀÇ»ç·Î¼­ ´À³¦À» ¸»ÇÏ´Â ¼ö ¹Û¿¡ ¾øÀ» °Í °°½À´Ï´Ù. Á¦ °³ÀÎ »ý°¢ÀÔ´Ï´Ù. ±Ù°ÅÀÚ·á... ±×·± °Í ¾ø½À´Ï´Ù. ±×·¯´Ï ¹Ï¾îµµ ÁÁ°í ¹ÏÁö ¾Ê¾Æµµ ÁÁ½À´Ï´Ù. Big data¸¦ °¡Áö°í ÀÖ´Â Á¤ºÎ¿¡¼­ ÀڷḦ ¸¸µé°í °ø°³ÇÏ´Â ¼ö ¹Û¿¡ ¾øÀ» °Í °°½À´Ï´Ù. ÀڷḦ ¹ÙÅÁÀ¸·Î Á¤Ã¥À» ¸¸µé°í, ÀڷḦ ¹ÙÅÁÀ¸·Î Á¤Ã¥À» ¼öÁ¤ÇÏ´Â ¹®È­°¡ ÇÊ¿äÇÕ´Ï´Ù.

ºñ±³Àû ÀþÀº ³ªÀÌ (40´ë, 50´ë)ÀÇ °ËÁø À§³»½Ã°æÀº ºÐ¸íÈ÷ µµ¿òµÇ´Â °Í °°½À´Ï´Ù. 60´ëÀÇ °ËÁø ³»½Ã°æÀº ÀþÀº ³ªÀ̺¸´Ù È¿°ú°¡ ´ú ÇÒ °¡´É¼ºÀÌ ÀÖÁö¸¸ ±×·¡µµ µµ¿òÀÌ µÈ´Ù°í »ý°¢ÇÕ´Ï´Ù. 70´ë´Â Àúµµ Àß ¸ð¸£°Ú½À´Ï´Ù. 80´ë´Â ¾Æ¸¶µµ ±ÇÇÏÁö ¾Ê´Â ÆíÀÌ ³ªÀ»Áö ¸ð¸£°Ú½À´Ï´Ù. °í·ÉÀÚ¿¡¼­ ¹«½ÉÄÚ ½ÃÇàÇÑ À§³»½Ã°æ °á°ú·Î °í¹Î ȤÀº °í»ýÇÏ´Â ºÐµéÀ» ³Ê¹« ¸¹ÀÌ º¸¾Ò½À´Ï´Ù.

°í·ÉÀÚ¿¡¼­ ¾Ï°ËÁø ³»½Ã°æ Áß´Ü ½ÃÁ¡À» Á¤ÇÏ´Â À̽´¿¡´Â ¼¼ °¡Áö ¾î·Á¿òÀÌ ÀÖ½À´Ï´Ù. ¿ì¸®³ª¶ó °íÀ¯ÀÇ ¾î·Á¿òÀÔ´Ï´Ù.

1) Çѹø ½ÃÀÛÇÑ ¼­ºñ½º´Â Áß´ÜÇϱ⠾î·Æ½À´Ï´Ù. °Ç°­°ü·Ã ¼­ºñ½º¸¦ ÀÏ´Ü ÁÖ¾ú´Ù°¡ ¹°¸®´Â °ÍÀº Á¤Ä¡ÀûÀ¸·Î ¾î·Á¿î ÀÏÀÔ´Ï´Ù. º¸¼ö Á¤´ç¿¡°Ô´Â ´õ¿í ¾î·Á¿î ÀÏÀÔ´Ï´Ù. °í·ÉÃþÀÇ ÁöÁö¸¦ Æ÷±âÇÒ ¼ö ¾ø±â ¶§¹®ÀÔ´Ï´Ù.

2) °ËÁø ³»½Ã°æ¿¡ ´ëÇÑ °¡°Ý À庮ÀÌ °ÅÀÇ ¾ø±â ¶§¹®¿¡ Áß´ÜÇϱ⠾î·Æ½À´Ï´Ù. ºñ¿ëÈ¿°ú·Î ¼³µæÇÒ ¼ö ¾ø±â ¶§¹®ÀÔ´Ï´Ù. ±¹°¡ Â÷¿ø¿¡¼­´Â ºñ¿ë È¿°ú¸¦ °í·ÁÇÒ ¼ö ÀÖÁö¸¸ °³ÀÎ Â÷¿ø¿¡¼­ À§³»½Ã°æ ºñ¿ëÀº °í·Á ¿ä¼Ò°¡ ¾Æ´Õ´Ï´Ù. °¡°ÝÀÌ ½Î¸é ÀûÀýÇÑ °¡À̵å¶óÀÎÀÌ¶óµµ ¸¸µé¾î µÎ¾ú¾î¾ß Çϴµ¥, ¾î¶°ÇÑ À庮µµ ¾øÀÌ ±×³É °¡°Ý¸¸ ³·Ãè½À´Ï´Ù. ¿Â°® ÀÌ»óÇÑ ÀÏÀÌ ÀϾ°í ÀÖ½À´Ï´Ù. ¼±½É¼º Á¤Ã¥ÀÇ ³ª»Û °á°ú°¡ ÀûÁö ¾Ê½À´Ï´Ù.

3) ¿ì¸®³ª¶ó´Â µ¿¹æ¿¹ÀÇÁö±¹ÀÔ´Ï´Ù. "¾î¸£½ÅÀº ÀÌÁ¦ ³»½Ã°æÀ» ±×¸¸ ¹ÞÀ¸¼¼¿ä"¶ó°í ¸»ÇÒ ¼ö ¾ø´Â ¹®È­ÀÔ´Ï´Ù. "±×·³ ÀÌÁ¦ Á×À¸¶õ ¸»À̳Ä?"°í ¹Ý¹®ÇÏ´Â ¾î¸£½ÅÀÌ °è½Ç ¼ö ÀÖ½À´Ï´Ù. ±ºÀÚÀÇ ³ª¶óÀÎ ¿ì¸®³ª¶ó¿¡¼­´Â Âü ¾î·Æ½À´Ï´Ù.

¾öû³­ »ç¾÷À» ´ëÃ¥¾øÀÌ ½ÃÀÛÇß´ø ½Ç¼ö°¡ ¾ÈŸ±î¿ï »ÓÀÔ´Ï´Ù. Pilot testµµ ¾øÀÌ ±×³É ¹Ð¾î ºÙÀÎ ±¹°¡ Á¤Ã¥ÀÇ ÇÇÇØ´Â °í½º¶õÀÌ ±¹¹Î¿¡°Ô µ¹¾Æ°©´Ï´Ù. ¾ÕÀ¸·Î´Â Á» ´õ õõÈ÷, Àß »ý°¢ÇÏ°í, pilot test¸¦ ÃæºÐÈ÷ ÇØ °¡¸é¼­ Á¤Ã¥À» ÆîÃijª°¡¾ß ÇÒ °ÍÀÔ´Ï´Ù.

ÀÇ»çµéÀº °í·ÉÀÚ¿¡°Ô ¹«¸®ÇÑ °ËÁø³»½Ã°æÀ» ±ÇÇÏÁö ¸»¾Æ¾ß ÇÏ°í, ¾î¸£½ÅµéÀº ½º½º·Î ¾Ë¾Æ¼­ Áß´Ü ½ÃÁ¡À» Á¤ÇØ¾ß ÇÕ´Ï´Ù. ±¹°¡ Á¤Ã¥ÀÌ ÀÌ»óÇÏ´Ï ±¹¹ÎÀÌ ¾Ë¾Æ¼­ ¿ÇÀº ±æÀ» ã¾Æ°¡¾ß ÇÏ´Â °ÍÀÌÁö¿ä. ¿ì½ÀÁö¸¸ ±×°Ô Çö½ÇÀÔ´Ï´Ù. °¡¸¸È÷ ÀÖÀ¸¸é ¾Æ¹«¸® °í·ÉÀÌ¶óµµ Á¤ºÎ¿¡¼­ °ËÁø ³»½Ã°æÀ» ¹ÞÀ¸¶ó´Â µüÁö¸¦ º¸³»¿É´Ï´Ù. ¿ì¸®³ª¶ó ÀÇ·á Çö½ÇÀÔ´Ï´Ù. ¾Ë¾Æ¼­ ÇൿÇÏ´Â ¼ö ¹Û¿¡ ¾ø½À´Ï´Ù. ÇҾƹöÁö, ÇÒ¸Ó´Ï°¡ ¾Ë¾Æ¼­ ÇൿÇÏ´Â ¼ö ¹Û¿¡ ¾ø°í, ÀڽĵéÀÌ ¾Ë¾Æ¼­ ì±â´Â ¼ö ¹Û¿¡ ¾ø½À´Ï´Ù.

Áú¹®ÇϽŠ³»¿ë Áß '80¼¼ ÀÌ»óÀº Á¶¿µ¼ú'À» ±ÇÇÑ´Ù´Â ³»¿ëÀº ±Ý½ÃÃʹ®ÀÔ´Ï´Ù. ³»½Ã°æÀ» ¹Þ±â ¾î·Á¿ï Á¤µµÀÇ °Ç°­»óŶó¸é Á¶¿µ¼úÀ» ±ÇÇÒ °ÍÀÌ ¾Æ´Ï¶ó screeningÀÇ ´ë»óÀÌ ¾Æ´Ï¶ó°í ¼³¸íÇØ¾ß ¿Ç½À´Ï´Ù. 80¼¼ À̻󿡼­´Â Á¶¿µ¼úÀ» ±ÇÇÑ´Ù´Â ¹æħÀº ¿Ã¹Ù¸¥ °ËÁøÀ̶ó°í º¸±â ¾î·ÆÁö ¾ÊÀ»±î¿ä?

ÇÑ ¸¶µð ´õ. ´ç¿¬ÇÑ À̾߱âÀÌÁö¸¸ ¾î´À ¿¬·ÉÀ̳ª °Ç°­»óŸ¦ °í·ÁÇÏ¿© °ËÁø °èȹÀ» ¼¼¿ö¾ß ÇÕ´Ï´Ù. À§¾ÏÀÌ ¹ß°ßµÇ´õ¶óµµ Ä¡·áÇϱ⠾î·Á¿î °Ç°­»óŶó¸é °ËÁø À§³»½Ã°æÀº ¹«ÀǹÌÇÒ »Ó´õ·¯ ÇØ°¡ µÇ±â ½±½À´Ï´Ù.


2. À§¾Ï °ËÁø ±Ç°í¾È¿¡ ¾ð±ÞµÈ °ËÁø À§³»½Ã°æ ¿¬·É »óÇѼ±

´ëÇÑÀÇ»çÇùȸÁö 2015³â 5¿ùÈ£¿¡ À§¾Ï °ËÁø ±Ç°í¾ÈÀÌ ¹ßÇ¥µÇ¾ú½À´Ï´Ù.

À̹ø °ËÁø ±Ç°í¾ÈÀÇ °¡Àå Áß¿äÇÑ Á¡Àº (1) À§³»½Ã°æ °Ë»ç¸¦ ±âº» °Ë»ç¹ýÀ¸·Î Á¦¾ÈÇÑ °Í°ú, (2) ¿¬·É »óÇѼ±À» ¼³Á¤ÇÏ¿´´Ù´Â °ÍÀÔ´Ï´Ù. " We recommend against gastric cancer screening for adults older than 85 years." À§¾Ï °ËÁø ±Ç°í¾ÈÀÇ Åä·Ð¿¡ Àß ¼³¸íµÇ¾î ÀÖ½À´Ï´Ù. Á¶¿µ¼ú¿¡ ºñÇÏ¿© ³»½Ã°æÀÌ ÈξÀ ÁÁ´Ù´Â °ÍÀº ´Ù ¾Æ´Â ÀÏÀÌ°í ´ÜÁö µ¥ÀÌŸ°¡ ºÎÁ·ÇÒ »ÓÀ̶ó´Âµ¥ ¸ðµÎ µ¿ÀÇÇÏ½Ç °ÍÀÔ´Ï´Ù. ¿©±â¼­´Â ¿¬·É »óÇѼ±¿¡ ´ëÇÑ ºÎºÐÀ» ¿Å±é´Ï´Ù.

°³Á¤ ±Ç°í¾ÈÀÇ ¶Ç ´Ù¸¥ Â÷ÀÌÁ¡À¸·Î´Â ±âÁ¸ ±Ç°í¾ÈÀÌ À§¾Ï °ËÁø ´ë»ó±ºÀ» 40¼¼ ÀÌ»óÀÇ ¼ºÀο¡¼­ »óÇÑ¿¬·É¿¡ ´ëÇÑ Á¦ÇѾøÀÌ ½Ç½ÃÇÏ°í ÀÖ¾ú´ø ¹Ý¸é, À̹ø °³Á¤¾È¿¡¼­´Â 75¼¼ À̻󿡼­´Â À̵æ°ú À§ÇØÀÇ Å©±â¸¦ ºñ±³Æò°¡ ÇÒ ¸¸ÇÑ ±Ù°Å°¡ ºÒÃæºÐÇϱ⠶§¹®¿¡ ±Ç°íµî±Þ I¸¦ ÁÖ¾î °ËÁøÀ» ¿øÇÏ´Â °æ¿ì °ËÁøÀ¸·Î ÀÎÇÑ À̵æ°ú À§ÇØ¿¡ ´ëÇÑ Á¤º¸¸¦ Á¦°øÇÏ°í °ËÁø¿©ºÎ¸¦ ÇÔ²² °áÁ¤Çϵµ·Ï ±Ç°íÇÏ¿´À¸¸ç, 85¼¼ À̻󿡼­´Â ±Ç°íµî±Þ D¸¦ ÁÖ¾î ½ÃÇàÇÏÁö ¸» °ÍÀ» ±Ç°íÇÏ¿´´Ù´Â Á¡ÀÌ´Ù. ÀÌ·¯ÇÑ °Ë»ç¹æ¹ýÀÇ º¯È­¿Í »óÇÑ¿¬·É µµÀÔÀÌ ¹ÌÄ¥ ÆÄÀåÀÌ ÀûÁö ¾ÊÀ» °ÍÀ¸·Î ÃßÁ¤µÇ¸ç, ½ÇÁ¦ ±Ç°í¾ÈÀ» Àϼ±¿¡¼­ ½ÇÇàÇÏ´Â µ¥ ÀÖ¾î ±íÀº °í·Á°¡ ÇÊ¿äÇÒ °ÍÀÌ´Ù.

¿¬·É »óÇѼ±À» ¼³Á¤ÇÑ °áÁ¤ÀûÀÎ ±Ù°Å´Â "±¹³» ¿¬±¸¿¡¼­ 75-84¼¼¿¡¼­´Â 1.09-1.15ÀÇ »ç¸Á ´ëÀÀÀ§Çèµµ¸¦ º¸¿© Åë°èÀûÀ¸·Î À¯ÀÇÇÑ »ç¸Á·üÀÇ °¨¼Ò°¡ º¸ÀÌÁö ¾Ê¾Ò°í, 85¼¼ À̻󿡼­´Â 2.15ÀÇ »ç¸Á ´ëÀÀÀ§Çèµµ¸¦ º¸¿© ¿ÀÈ÷·Á ¼±º°°Ë»ç¿¡ µû¸¥ »ç¸Á·üÀÇ Áõ°¡°¡ ³ªÅ¸³µ´Ù"´Â °ÍÀÔ´Ï´Ù. ÃÊ°í·É¿¡¼­ °ÇÁø ³»½Ã°æÀ» ÇÏ¸é ¿ÀÈ÷·Á ÀÏÂï µ¹¾Æ°¡½Ç ¼ö ÀÖ´Ù´Â ÀÇ·áÁøÀÇ °æÇèÀ» ¼öÄ¡È­ÇÏ¿© º¸¿©ÁØ Áß¿äÇÑ µ¥ÀÌŸ¶ó°í »ý°¢ÇÕ´Ï´Ù. °í·É¿¡¼­ ³»½Ã°æÀ» ±ÇÇÒ ¶§ ¸í½ÉÇØ¾ß ÇÒ »çÇ×ÀÌ ¾Æ´Ò ¼ö ¾ø½À´Ï´Ù.


3. ´ëÀå¾Ï °ËÁø Áß´Ü ½ÃÁ¡ - Â÷Àç¸í ±³¼ö´ÔÀÇ ¸®ºä (2015)

°æÈñ´ë Â÷Àç¸í ±³¼ö´ÔÀÇ ÃÖ±Ù ¸®ºä (Intest Res 2014)¸¦ ¼Ò°³ÇÕ´Ï´Ù. Á¦¸ñÀº Would you recommend screening colonoscopy for the very elderly? »ý°¢°Å¸®°¡ ¸¹Àº ÁÁÀº ¸®ºäÀÔ´Ï´Ù.

Â÷±³¼ö´ÔÀº personal heuristics¸¦ ¾ð±ÞÇϼ̽À´Ï´Ù. Behavioral psychology¿¡¼­ »ç¿ëÇÏ´Â heuristics¶ó´Â ¸»Àº '°æÇè¿¡ ±âÃÊÇÑ ÆÇ´Ü' Á¤µµÀÇ ÀǹÌÀÔ´Ï´Ù. µû¶ó¼­ ÀÇ»ç °³ÀÎÀÇ °æÇè¿¡ ÀÇÇÑ ¿µÇâÀÌ Å©´Ù´Â ¸»ÀÔ´Ï´Ù.

"Therefore, whether clinicians should perform colonoscopy screening and when colonoscopy screening should be discontinued in the very elderly are ongoing controversial issues and decisions in this regard seem to be based on clinical judgement, with frequent reliance on personal heuristics.

Çѱ¹Àû »óȲ¿¡ ´ëÇÏ¿© ¾ð±ÞÇÑ ¹®´ÜÀÌ ÀÖ¾ú½À´Ï´Ù. Á¤º¸¸¦ Á־ Àß ÆÇ´ÜÇϵµ·Ï µµ¿Í¾ß ÇÑ´Ù´Â ¸»ÀÔ´Ï´Ù. ±×³É ¸»¸®Áö ¸»°í Àß °¡¸£Ãļ­ ½º½º·Î ¾È ÇÏ´Â ¹æÇâÀ¸·Î °áÁ¤Çϵµ·Ï ÇØ¾ß ÇÑ´Ù´Â °ÍÀε¥ ½±Áö ¾ÊÀº ÀÏ °°½À´Ï´Ù. Very elderly personÀÌ intelligent decisionÀ» Çϵµ·Ï informationÀ» ÁÖ¾î¾ß ÇÑ´Ù´Â °ÍÀ¦ ½±Áö ¾ÊÀº ÀÏ °°½À´Ï´Ù. ±×³É Àǻ簡 ȤÀº Á¤ºÎ°¡ Á¤ÇØÁÖ´Â ÆíÀÌ ³´Áö ¾ÊÀ»±î¿ä?

With the current health-case system and the Confucian culture in Korea, restriction of screening colonoscopy on the basis of upper age criteria may rarely be imposed. For example, it may not be easy for colonoscopists to refuse the request for screening colonoscopy by very elderly patients. However, such individuals may make more intelligent decisions if they are fully informed about the balance between the risks and benefits of screening colonoscopy as well as the possible alternatives (including no diagnostic work up at all). Colonoscopists should help the very elderly patients make the best informed decision while respecting the patients¡¯ right to the final decision.


4. °ËÁøÀÇ bias¿Í °ËÁø ³»½Ã°æ ¿¬·É»óÇѼ±¿¡ ´ëÇÑ °íÂû [2015-4-4. À§¾ÏÇÐȸ KINGCA 2015 °­ÀÇ ÀϺΠ¹ßÃé]

There are two important biases in the cancer screening. The first one is very famous, the lead time bias. I think all individuals in this hall already understand this type of bias. Even if we may detect cancers earlier, the overall survival gain is another issue due to the lead time bias.

The second bias is the length-time bias. It means cancers detected in the screening program may be less aggressive. This bias is especially important for the elderly population. If some cancers in the elderly people are very slow-growing, is there any reason that we need to find them?

Survival gain by the cancer screening is usually like this. At some age, the survival gain can be zero. After that point, screening can actually decrease the individual¡¯s survival. We need to stop before that age. But, the problem here is that we don¡¯t know exactly when to stop.

In terms of screening for cancers, we need to consider the life expectancy. Screening tests are usually recommended when the expected survival is longer than 10 years. In this regard, screening at the age of 80 is usually not recommended.

Do you know the Hoerr¡¯s law? It means it is difficult to make the asymptomatic patient feel better. Regarding the screening in the elderly population, we need to ask to ourselves. We are really making the elderly people feel better, be happier by all the screening and aggressive treatment?

A few years ago, US preventive services task force recommended against routine colonoscopy for adults with ages 76 to 85.

This is one of many evidences supporting the US preventive services task force recommendations. After 75 years, screening colonoscopy showed no more benefit. Actually, screening colonoscopy after 75 years makes more and more complications. 75 is a good age for stopping screening colonoscopy.

As a box summary, I can say that more is not always better, especially in the cancer screening in the elderly. Sometimes, less may be better. We need to stop at some point.


[Cases]

94¼¼ ¿©¼ºÀ¸·Î Æó¾Ï, °íÇ÷¾Ð, ÇãÇ÷¼º ´ëÀå¿° µîÀ¸·Î Àå±â°£ °í»ýÀÌ ¸¹À¸¼Ì´ø ºÐÀÔ´Ï´Ù. ¾î´À ³¯ °ÇÁø ³»½Ã°æ¿¡¼­ ¹ß°ßÇÑ À§¼±Á¾¿¡ ´ëÇÏ¿© ÀÜ¶à °ÌÀ» ¸Ô°í °ÆÁ¤À» Çϸ鼭 Àú¸¦ ã¾Æ¿À¼Ì½À´Ï´Ù. ÇãÇ÷¼º ´ëÀå¿° ¶§ Ä¡·áÇصå·È´ø Àο¬ÀÌ ÀÖ¾ú½À´Ï´Ù. 94¼¼À̽ŵ¥ ¾î¶² Á¾ÇÕ°ËÁø¼¾ÅÍ¿¡¼­ Á¾ÇÕ°ËÁøÀ» ¹ÞÀ¸¼Ì´Ù°í ÇÕ´Ï´Ù. ¾î󱸴ϰ¡ ¾ø¾ú½À´Ï´Ù. Çϵµ °ÆÁ¤ÀÌ ¸¹À¸½ÅÁö¶ó ³»½Ã°æ ¼ÒÀÛ¼úÀ» ÇØ µå·È½À´Ï´Ù. »ç½Ç Ä¡·á°¡ ÇÊ¿äÇÒÁö Àǹ®À̾úÁö¸¸, ¿ö³« °ÆÁ¤ÀÌ ¸¹À¸¼Ì°í ½Ã¼úÀº »ó´ëÀûÀ¸·Î °£´ÜÇÏ¿© (ÀÔ¿øµµ ÇÊ¿ä¾ø°í 5ºÐÀ̸é ÃæºÐ) ¼ÒÀÛ¼úÀ» ÇØ µå·È½À´Ï´Ù. Âü º° Àϵµ ´Ù ÀÖ½À´Ï´Ù. ¾î¿ ¼ö ¾øÀÌ °£´ÜÇÑ Ä¡·á¸¦ ÇØ µå·È½À´Ï´Ù¸¸...

°í·ÉÀÚ ´ëÀå³»½Ã°æ »ó´ã ¿¹

88¼¼ ¿©¼ºÀÇ °ËÁø ³»½Ã°æ¿¡¼­ ¹ß°ßµÈ Hp (-) MALToma. ¿Ö °ËÁøÀ» ¹ÞÀ¸¼ÌÀ»±î?


ESD for EGC of an elderly gentlemen was done. He was 98 years old by his ID (Áֹεî·ÏÁõ). He said that he is actually a little bit younger than that. Anyway still very elderly.


ESD : Early gastric carcinoma
1. Location : proximal antrum, anterior wall
2. Gross type : EGC type IIc
3. Histologic type : tubular adenocarcinoma, moderately differentiated
4. Histologic type by Lauren : intestinal
5. Size of carcinoma : (1) longest diameter, 14 mm (2) vertical diameter, 8 mm
6. Depth of invasion : invades mucosa (muscularis mucosa) (pT1a)
7. Resection margin : free from carcinoma(N), safety margin : distal 10 mm, proximal 7 mm, anterior 10 mm, posterior 8 mm, deep 600 §­
8. Lymphatic invasion : not identified(N)
9. Venous invasion : not identified(N)
10. Perineural invasion : not identified(N)
11. Microscopic ulcer : absent
12. Histologic heterogeneity: absent

There is a debate about the upper age limit of the screening endoscopy. By the data, it is 75 years. In the daily practice, it seems to be 200 years.

I wonder whether follow-up examinations are necessary for him. I would not recommend, but he may want some tests. I don't know what to do.


[FAQ]

[2014-10-11. ¾Öµ¶ÀÚ ÆíÁö]

"ºñ±³Àû ÀþÀº ³ªÀÌ (40´ë, 50´ë)ÀÇ °ËÁø À§³»½Ã°æÀº ºÐ¸íÈ÷ µµ¿òµÇ´Â °Í °°½À´Ï´Ù. 60´ëÀÇ °ËÁø ³»½Ã°æÀº ÀþÀº ³ªÀ̺¸´Ù È¿°ú°¡ ´ú ÇÒ °¡´É¼ºÀÌ ÀÖÁö¸¸ ±×·¡µµ µµ¿òÀÌ µÈ´Ù°í »ý°¢ÇÕ´Ï´Ù. 70´ë´Â Àúµµ Àß ¸ð¸£°Ú½À´Ï´Ù. 80´ë´Â ¾Æ¸¶µµ ±ÇÇÏÁö ¾Ê´Â ÆíÀÌ ³ªÀ»Áö ¸ð¸£°Ú½À´Ï´Ù."¶ó´Â ±³¼ö´ÔÀÇ ¸»¾¸¿¡ µ¿ÀÇÇÕ´Ï´Ù. Cancer risk period ¶ó´Â ¿ë¾î·Î 40-60´ë »çÀ̸¦ ¼³¸íÇÒ ¼ö ÀÖÀ» °Í °°½À´Ï´Ù. ¿ÀÈ÷·Á 70/80´ë´Â cancer risk°¡ ¶³¾îÁöÁö ¾Ê³ª »ý°¢ÇÕ´Ï´Ù. °Ç°­°ËÁøµµ 2³â °£°ÝÀÇ È¹ÀÏÀû °Ë»ç¿¡¼­ Å»ÇÇÇؼ­ »õ·Î¿î °³³äÀ¸·Î Á¤¸®µÇ¾î¾ß ÇÒ °ÍÀÔ´Ï´Ù. ¶ÇÇÑ, ¹Ì±¹¿¡¼­ USPSTF °¡À̵å¶óÀÎÀÌ ´º½º¸¦ ÅëÇØ Àß Àû¿ëµÇ´Â °Í ó·³, ¿ì¸®³ª¶óµµ °¢ ÇÐȸ¿¡¼­ °¡À̵å¶óÀÎÀ» Á¤ÇÏ°í ÀÖÀ¸³ª, ¹Ì±¹Ã³·³ ±×·± °¡À̵å¶óÀÎÀÇ ¿ªÇÒÀ» Çϱâ±îÁö ½Ã°£ÀÌ °É¸± µí ÇÕ´Ï´Ù.


[2015-5-5. ȯÀÚ º¸È£ÀÚ Áú¹®]

Å« °íµµ¼±Á¾À¸·Î ÀÇ·ÚµÈ È¯ÀÚÀÇ º¸È£ÀÚ°¡ °í·É(80´ë Áß¹Ý)Àε¥ ³»½Ã°æ Ä¡·á°¡ ÇÊ¿äÇÑ°¡ ¹®ÀÇÇÏ¿©¼­ ¾Æ·¡¿Í °°ÀÌ ´äÇØ µå·È½À´Ï´Ù.


[2015-8-19. ¾Öµ¶ÀÚ ÆíÁö - ´ëÀå¾Ï °ËÁø ±Ç°í¾È¿¡ ´ëÇÏ¿©]

°ËÁø¼¾ÅÍ¿¡¼­ ÀÏÇÏ°í ÀÖ½À´Ï´Ù. °£È¤ 80´ë ÀÌ»óÀÎ ºÐµé²²¼­ À§/´ëÀå ³»½Ã°æ °Ë»ç¸¦ À§ÇØ ¹æ¹®ÇÏ°ï ÇϽʴϴÙ. °í·É¿¡ °ËÁøÀ» ¹Þ´Â ÀÌÀ¯¿¡ ´ëÇØ Á¶½É½º·´°Ô ¿©Â庸¸é, 60-70´ë¿¡µµ Á¤±âÀûÀ¸·Î À§/´ëÀå °Ë»ç¸¦ ¹Þ¾Æ¿À¼Ì±â ¶§¹®¿¡ ¶§°¡ µÇ¾î¼­ ÀÚ¿¬½º·´°Ô ¹ÞÀ¸·¯ ¿À½Å ºÐµéµµ °è½ÃÁö¸¸, ÃÖ±Ù 1-2³â »çÀÌ¿¡ ¸î¸î °ËÁø ¾÷üÀÇ ¹«ºÐº°ÇÑ °ËÁøÀ» ¹ÞÀº ´ÙÀ½¿¡ annual f/u Ç϶ó´Â ÄÚ¸àÆ®¸¦ ¹Þ°í ¿À½Å ºÐµéµµ °è½Ê´Ï´Ù.

³ëÀÎÁ¤À̳ª ¾ç·Î¿ø µîÀ» ¹æ¹®ÇØ ¾î¸£½ÅµéÀ» ´Üü·Î ¸ðÁýÇØ ¿À´Â °æ¿ìµµ ÀÖ´Ù°í ÇÕ´Ï´Ù. ÀÌ·¸°Ô º´¿ø¿¡ ¿À½Å ºÐµé Áß¿¡´Â ½ÉÁö¾î º»ÀÎÀÌ ³»½Ã°æÀ» ¹ÞÀ¸·¯ ¿Ô´Ù´Â »ç½Çµµ ¸ð¸£´Â ºÐµéÀÌ ¸¹´Ù°í ÇÕ´Ï´Ù.

±¹°¡¾ÏÁ¤º¸¼¾ÅÍ¿¡¼­ 2015/4 ¿ù¿¡ ´ëÀå¾Ï °ËÁø ±Ç°í¾È ÃʾÈÀÌ ³ª¿Ô´Âµ¥ ´ëÀå³»½Ã°æ °ü·Ã Ãßõ µî±Þ C¿¡ ´ëÇÏ¿© ³í¶õÀÌ µÇ¾ú´ø ±â¾ïÀÌ ÀÖ½À´Ï´Ù. ¾Ï°ÇÁø °ü·ÃÀ¸·Î ÇÔ²² ¼Ò°³ÇØ Áֽøé ÁÁÀ» °Í °°½À´Ï´Ù.

[2015-8-30. ÀÌÁØÇà ´äº¯]

°¨»çÇÕ´Ï´Ù. ÀÇÇùÁö¿¡ ½Ç¸° ´ëÀå¾Ï °ËÁø ±Ç°í¾È (2015)À» ¹ÙÅÁÀ¸·Î ´äº¯µå¸³´Ï´Ù. ÁöÀûÇϽŠ¹Ù¿Í °°ÀÌ ±âº» ´ëÀå¾Ï ¼±º°°Ë»ç´Â ºÐº°ÀáÇ÷°Ë»çÀÌ°í, ´ëÀå³»½Ã°æÀº ¼±ÅÃÀûÀ¸·Î ½ÃÇàÇϵµ·Ï ±Ç°íµÇ¾ú½À´Ï´Ù.

±Ç°í¹®: ´ëÀå³»½Ã°æ¿¡¼­ À̵æÀÇ ±Ù°Å¼öÁØÀº Áߵ(moderate)À̸ç, À§ÇØÀÇ ±Ù°Å¼öÁØÀº ³·À½(low)·Î ºñ±³ °á°ú À̵æÀÇ Å©±â°¡ ÀÛÀ½(small)À̾ú´Ù. ¹«Áõ»ó ¼ºÀο¡ ´ëÇÑ ´ëÀå³»½Ã°æÀ» °³Àκ° À§Çèµµ¿¡ ´ëÇÑ ÀÓ»óÀû ÆÇ´Ü°ú ¼ö°ËÀÚÀÇ ¼±È£µµ¸¦ °í·ÁÇÏ¿© ¼±ÅÃÀûÀ¸·Î ½ÃÇàÇÒ °ÍÀ» ±Ç°íÇÑ´Ù(±Ç°íµî±Þ C).

¼³¸í:´ëÀå³»½Ã°æÀº ´ëÀå¾Ï »ç¸Á·ü°ú ¹ß»ý·üÀ» À¯ÀÇÇÏ°Ô °¨¼Ò½ÃÄÑ ´ëÀå¾Ï ¼±º°°Ë»ç·Î¼­ È¿°ú¸¦ º¸ÀÌÁö¸¸, ´ëÀå³»½Ã°æÀÇ À§ÇØ Áß Áß´ëÇÑ ÇÕº´ÁõÀÇ ¹ß»ý·üÀº 0-0.47%, »ç¸ÁÀÇ ¹ß»ý·üÀº 0-0.06%, 5³â °£°ÝÀÇ ´ëÀå³»½Ã°æ ½ÃÇà ½Ã Áß°£¾Ï ¹ß»ýÀÇ À§ÇèÀº 4.6-5.4%·Î ¼±º°°Ë»ç·Î¼­ÀÇ ´ëÀå³»½Ã°æÀÇ À̵æ°ú À§ÇØÀÇ ºñ±³°á°ú À̵æÀÇ Å©±â°¡ "ÀÛÀ½(small)"À¸·Î °áÁ¤ÇÏ¿´´Ù.

À̹ø °áÁ¤¿¡´Â ´ëÀå³»½Ã°æ °ü·Ã õ°ø ¹× »ç¸Á À§ÇèÀÌ Å©°Ô ¿µÇâÀ» ¹ÌÄ£ °Í °°½À´Ï´Ù. ´ëÀå³»½Ã°æÀº ½Ã¼úÀÚÀÇ ¼÷·Ãµµ¿¡ µû¶ó Áø´ÜÀ²°ú ÇÕº´Áõ ¹ß»ý·üÀÌ Å©°Ô ´Þ¶óÁý´Ï´Ù. ¾ö°ÝÇÑ Áú°ü¸® ÇÁ·Î±×·¥ÀÌ È®¸³µÇÁö ¸øÇÑ Çö »óÅ¿¡¼­ Àü±¹¹Î ´ë»ó ±âº» ¼±º°°Ë»ç·Î äÅÃÇϱ⠾î·Á¿üÀ» °ÍÀÔ´Ï´Ù.

Àú´Â ³»½Ã°æÀ» ¾÷À¸·Î »ì°í ÀÖÁö¸¸, À̹ø °áÁ¤¿¡´Â Âù¼ºÇÏ´Â ÂÊÀÔ´Ï´Ù. 'Àü±¹¹Î ´ë»ó ±âº» ¼±º°°Ë»ç'´Â ¾Æ¹«·¡µµ ¾ÈÀü¼º È®º¸°¡ Áß¿äÇϱ⠶§¹®ÀÔ´Ï´Ù. ºñ´Ü ÆíÁö¿¡¼­ ¾ð±ÞµÈ »ç·Ê°¡ ¾Æ´Ï´õ¶óµµ ÇöÀç ±¹°¡ ¾Ï°ËÁø ÇÁ·Î±×·¥Àº º°´Ù¸¥ ¼³¸íµµ ¾øÀÌ ¸¶±¸ÀâÀÌ·Î °Ë»çÇÏ´Â ¼öÁØÀ» ¹þ¾î³ªÁö ¸øÇÏ°í ÀÖ½À´Ï´Ù. °Ë»ç¹æ¹ýÀ» º¯°æÇϰųª ´ë»óÀ» È®´ëÇϱâ ÀÌÀü¿¡ ±³À°/Àç±³À°À» Æ÷ÇÔÇÑ ÁúÇâ»ó ÇÁ·Î±×·¥ÀÌ Àß ÀÛµ¿µÇ¾î¾ß ÇÒ °ÍÀÔ´Ï´Ù.

´ëÀå¾Ï ¼±º°°Ë»ç ¿¬·É »óÇѼ±ÀÌ 80¼¼·Î µÇ¾î ÀÖ´Â °ÍÀº ´Ù¼Ò ÀÇ¿Ü¿´½À´Ï´Ù. 75¼¼°¡ µÉ ÁÙ ¾Ë¾Ò´Âµ¥ °á°ú¸¦ ¹Ù¶óº¸´Â ½Ã¼±ÀÌ Àú¿Í´Â Á¶±Ý ´Ù¸¥ °Í °°½À´Ï´Ù. À§¾ÏÀº 75¼¼, ´ëÀå¾ÏÀº 80¼¼·Î ±Ç°íµÈ ÀÌÀ¯¸¦ Àú´Â ¾ËÁö ¸øÇÕ´Ï´Ù. ¾Æ¸¶ À§¾Ï ÆÀ°ú ´ëÀå¾Ï ÆÀÀÌ µ¶¸³ÀûÀ¸·Î ÀÛ¾÷ÇÏ¿´´ø °Í °°½À´Ï´Ù.

´ëÇк´¿ø¿¡¼­ Á¶Â÷µµ ±Ç°í¾ÈÀ» ÃÊ°úÇÏ´Â ¹æ½ÄÀ¸·Î °ËÁøÀÌ ÁøÇàµÇ´Â °Í¿¡ ´ëÇÏ¿© ÀÚ±«°¨À» °¡Áö°í ÀÖ½À´Ï´Ù.

[2015-8-31. ¾Öµ¶ÀÚ ÆíÁö]

À§¾Ï°ú ´ëÀå¾ÏÀº ÀüÇô º°µµÀÇ À§¿øÀÌ Âü¿©ÇÏ¿´°í, ¼­·ÎÀÇ °ËÁø¾È µµÃâ °úÁ¤À» ¾ËÁö ¸øÇÏ¿´½À´Ï´Ù (¹«½¼ ±â¹Ð »çÇ×µµ ¾Æ´Ï°í... ¾ÏÁ¾º° °ËÁø TFT°¡ ÅëÀϼº ¾øÀÌ ÀüÇô º°µµÀÇ °úÁ¤À¸·Î ÁøÇàµÈ °ÍÀº Á» ¹®Á¦°¡ ÀÖ¾ú½À´Ï´Ù....)

À§¾ÏÀº ±¹³»ÀÇ 10³â°£ ±¹°¡¾Ï°ËÁø »ç¾÷ÀÇ °á°ú¸¦ ºÐ¼®ÇÑ ¿¬±¸¿¡¼­ 75-84¼¼¿¡¼­´Â °ËÁøÀÇ µû¸¥ À̵æÀÌ Áõ¸íµÈ ¹Ù ¾ø°í, 85¼¼ À̻󿡼­´Â °ËÁø±º¿¡¼­ ¿ÀÈ÷·Á À§¾Ï ¹× Àüü »ç¸Á·üÀÌ Áõ°¡ÇÑ´Ù´Â °á°ú¸¦ º¸¿©

1) 75-84¼¼´Â °³°³ÀÎÀÇ À̵æ°ú À§ÇèÀ» °í·ÁÇÏ¿© ½ÃÇà ¿©ºÎ¸¦ °áÁ¤ÇÑ´Ù

2) 85¼¼ ÀÌ»óÀº ±Ç°íÇÏÁö ¾Ê´Â´Ù

¶ó´Â ±Ç°í¾ÈÀ» ¹ßÇ¥ÇÑ ¹Ù ÀÖ½À´Ï´Ù. ´ëÀå¾ÏÀÇ 80¼¼ °áÁ¤ ±Ù°Å´Â Àß ¸ð¸£°Ú½À´Ï´Ù....


[2017-8-5. ¾Öµ¶ÀÚ Áú¹®]

1. À§ Á¡¸·ÇÏÁ¾¾ç ÀÇ½É È¯ÀÚÀÔ´Ï´Ù. °ú°ÅºÎÅÍ À̹ø±îÁö ³»½Ã°æ »çÁøÀ» °ËÅäÇÑ ¹Ù ±Ë¾ç ¹ÝÈçÀÎÁö ectopic pancreasÀÎÁö ¸íÈ®ÇÏÁö ¾Ê¾Ò½À´Ï´Ù. ´ÜÁö ¼ö³â°£ º¯È­°¡ ¾ø´Ù´Â °ÍÀº È®½ÇÇÕ´Ï´Ù. ÀÌ º´º¯ÀÌ ±×Àú ¿¹Àü¿¡ ±Ë¾çÀÌ ÀÖ´Ù°¡ È£ÀüµÈ central depression scar·Î º¸°í 2³â ÈÄ ³»½Ã°æÀ» ±ÇÇÒÁö, ¶Ç´Â r/o ectopic pancreas¶ó°í ¼³¸íµå¸®°í 2³â ÈÄ ³»½Ã°æÀ» ±ÇÇÒÁö, ±×·¡µµ 1³â ÈÄ Àç°ËÀ» ±ÇÇÏ´Â °ÍÀÌ ¸ÂÀ»Áö, ¾Æ´Ï¸é 79¼¼ÀÌ°í multiple myelomaµµ °¡Áö°í ÀÖÀ¸´Ï reassuranceÇÏ°í ÀØ°í Áö³»¶ó°í ÇÏ´Â °ÍÀÌ ¸ÂÀ»Áö °í¹ÎÀÔ´Ï´Ù. (CT ³ª EUS¸¦ ±ÇÇϱ⿣.....) Áõ»óÀº ¼ÒÈ­ºÒ·®, ±¸Åä µî °è¼Ó Áõ»óÀº ÀÖÀ¸¼Ì´ø ºÐÀÔ´Ï´Ù.

2. ¿ä»õ °ËÁø Â÷¿øÀÇ À§³»½Ã°æÀ̳ª ´ëÀå³»½Ã°æÀ» ¿øÇÏ´Â 75¼¼ ÀÌ»óÀÇ È¯Àڵ鿡°Ô ±»ÀÌ °í»ý½º·¯¿î °Ë»ç¸¦ ´õ ÇÏ½Ç ÇÊ¿ä°¡ ¾ø¾îº¸Àδٴ ¸»¾¸À» µå·È´ø ÀûÀÌ Àִµ¥, ȯÀÚºÐÀÌ "Çϱä ÀÌÁ¦ ³ªÀ̵µ ¸¹ÀÌ ¸Ô¾úÀ¸´Ï..." Çϸ鼭 ¿ÀÈ÷·Á ¾¹¾µÇØÇϽðí, Á÷Á¢ ¸»¾¸À» ¾ÈÇϼÌÁö¸¸ ¼­¿îÇØÇϽô °Í °°¾Æ¼­.... ´Ù½Ã ±×·± ¸»Àº ¾ÈÇؾ߰ڴÙ, 100¼¼ ½Ã´ë À̾߱⵵ ³ª¿À´Âµ¥.... ÀÌ·± »ý°¢ÀÌ µé°ïÇÕ´Ï´Ù... ^^;;;

[2017-8-7. ÀÌÁØÇà ´äº¯]

Ectopic pancreas ȤÀº ulcer scar Áß Á¤È®ÇÑ Áø´ÜÀÌ ¹«¾ùÀ̵ç ÀÌ°ÍÀÌ È¯ÀÚÀÇ ÀÓ»ó°æ°ú¿¡ Å« ¹®Á¦¸¦ ÀÏÀ¸Å°Áö ¾ÊÀ» °Í °°¾Æ º¸ÀÔ´Ï´Ù.

¿¬·ÉÀ» °í·ÁÇÏÁö ¾Ê°í Áúº´¸¸ °ÆÁ¤ÇÏ¿© ºÒÇÊ¿äÇÑ °Ë»ç¿Í ¾î¼¸é ºÒÇÊ¿äÇÑ Ä¡·á¸¦ ¹Þ´Ù°¡ ¿ÀÈ÷·Á ÀÏÂï µ¹¾Æ°¡½Ã´Â ȯÀÚ¸¦ Á¾Á¾ ¸¸³³´Ï´Ù. Â÷¶ó¸® ¸ð¸£°í Áö³»´Â °ÍÀÌ ³ª¾Ò°Ú´Ù ½ÍÀº ¿¹°¡ ÀûÁö ¾Ê½À´Ï´Ù. ÀÚ½ÅÀÇ ¿¬·É°ú °Ç°­»óŸ¦ °í·ÁÇÏÁö ¾Ê°í ¹«ÇÑ °Ë»ç¸¦ ¿øÇÏ´Â °ÍÀº À¯ÇÑÇÑ »ý¸íÀ» °¡Áø »ç¶÷À̶ó´Â »ý¸íü ´©±¸³ª °¡Áú ¼ö ÀÖ´Â »ý°¢ÀÔ´Ï´Ù. ±×·¯³ª ȯÀÚ°¡ ¼·¼·ÇØ ÇÑ´Ù°í upper age limit ¾øÀÌ ¹«ÇÑÈ÷ °Ë»ç¸¦ ¹Ýº¹ÄÉÇÏ´Â °ÍÀº ¿Ã¹Ù¸¥ ÀÇ»çÀÇ Åµµ´Â ¾Æ´Ò °ÍÀÔ´Ï´Ù. ¼ö³â°£ º¯È­°¡ ¾ø´Â À§ ÀüÁ¤ºÎ SMTÀÌ°í, 79¼¼ multiple myeloma ȯÀÚ¶ó¸é ±×³É Àû´çÈ÷ µÑ·¯´ë¸é¼­ -- ¿¹¸¦ µé¾î ¼ö³â°£ º¯È­°¡ ¾øÀ¸´Ï ÀÌÁ¦ °Ë»ç °£°ÝÀ» ´Ã·Áº¸µµ·Ï ÇսôÙ. 2-3³â ÈÄ¿¡ µé·¯ÁÖ¼¼¿ä -- ´õ ÀÌ»óÀÇ ÃßÀû ³»½Ã°æ °Ë»ç¸¦ ÃßõÇÏÁö ¾Ê´Â °ÍÀÌ ºÎµå·¯¿î ¹æ¹ýÀÏ °Í °°½À´Ï´Ù.

°ËÁø upper age limit´Â ÀϹÝÀûÀÎ °¡À̵åÀÔ´Ï´Ù. ¿¬·ÉÀÌ ¸¹´õ¶óµµ ¾ÆÁÖ °Ç°­ÇÏ°í º»ÀÎÀÇ ÀÇ¿åÀÌ °­Çϸé screeningÀ» ÇÒ ¼ö ÀÖ´Â °ÍÀÌ°í, ¿¬·ÉÀÌ ÀÌ¿¡ ¹ÌÄ¡Áö ¸øÇÏ´õ¶óµµ ´Ù¸¥ Àå±â Áúº´ µîÀ¸·Î expected survivalÀÌ 10³â (ȤÀº 5³â) ¹Ì¸¸À̶ó¸é screening endoscopyÀÇ ´ë»óÀº ¾Æ´Ï¶ó°í »ý°¢ÇÕ´Ï´Ù.


[2015-2-7. ¾Öµ¶ÀÚ ÆíÁö]

À۳⠸»¿¡ ºÐº¯ÀáÇ÷ ¾ç¼ºÀÎ ¸¸ 89¼¼ ÇҾƹöÁö¸¦ ´ë»óÀ¸·Î ´ëÀå³»½Ã°æÀ» ÇØ ºÃ½À´Ï´Ù. Á¦°¡ ±Ù¹«ÇÏ´Â XX³»°ú¿¡¼­ Àú¶û °°ÀÌ ÀÏÇϽô ÇÑ ¿øÀå´ÔÀÌ ±¹°¡°ËÁø °á°ú¿¡¼­ ºÐº¯ÀáÇ÷ ¾ç¼ºÀÌ ³ª¿Â ¸¸ 89¼¼(¿ì¸®³ªÀÌ·Î)ÀÎ ÇÑ ÇҾƹöÁö°¡ ÀÖ¾ú´Âµ¥, ¿¬¼¼¿¡ ºñÇØ ºñ±³Àû Á¤Á¤Çϼż­ ´ëÀå³»½Ã°æ °Ë»ç¸¦ ±Ç°íÇϼ̴ٰí ÇÕ´Ï´Ù. ÀÌ ¿øÀå´ÔÀº °ú°Å¿£ ´ëÀå³»½Ã°æ °Ë»ç¸¦ Çغ¸¼ÌÁö¸¸ ÇöÀç´Â ´ëÀå³»½Ã°æ °Ë»ç´Â ¾È ÇϽðí À§³»½Ã°æ °Ë»ç¸¸ ÇÏ°í °è½Ê´Ï´Ù.

¾î·µç ±×ºÐ ¾Æµå´ÔÀÌ °Ë»ç ¿¹¾àÀ» Çϼż­ ´ëÀå³»½Ã°æ °Ë»ç´Â Á¦°¡ ÇÏ°Ô µÇ¾ú½À´Ï´Ù. Á¦°¡ ´ëÀå³»½Ã°æÀ» ÇÑ °æ¿ì Áß ¸¸ 89¼¼³ª µÇ´Â °æ¿ì´Â óÀ½À̶ó Á¶½É½º·¯¿ü´Âµ¥, À̺ÐÀÌ ´ëÀå³»½Ã°æÀ» ÀÌÀü¿¡ Çغ¸½Å ÀûÀÌ ¾ø¾î¼­ ±×·±Áö 1~2 cm Á¤µµ µÇ´Â Å« ¿ëÁ¾µéÀÌ 3-4°³ Á¤µµ À־ ¿ëÁ¾ÀýÁ¦¼úµµ ÇØ¾ß Ç߱⿡ ´õ¿í Á¶½É½º·¯¿ü½À´Ï´Ù. ´ÙÇàÈ÷ °Ë»ç´Â Àß ³¡³µÁö¸¸, °Ë»ç ÈÄ¿¡ ÀÌ ÇҾƹöÁö¿¡°Ô °Ë»ç¸¦ ±Ç°íÇϽŠ¿øÀå´Ô²² ¸¸ 85¼¼°¡ ³Ñ¾î°¡¸é À¢¸¸ÇÏ¸é ´ëÀå³»½Ã°æ °Ë»ç´Â ±Ç°íÇÏÁö ¾ÊÀ¸½Ã´Â °ÍÀÌ ÁÁ°Ú´Ù°í ¸»¾¸µå·È½À´Ï´Ù. Ȥ½Ã¶óµµ ¹®Á¦°¡ »ý±â¸é Å« ¼ö¼úÀÌ ÇÊ¿äÇÒ ¼ö Àִµ¥, ±× °æ¿ì °¨´çÇϱⰡ ¾î·Á¿öÁö´Ï±î¿ä. Á¦ »ý°¢¿¡´Â Á¤Á¤ÇÏ½Ã¸é ¸¸ 85¼¼±îÁö´Â °¡´ÉÇÒ °Í °°°í, Á¶±Ý ¹®Á¦°¡ ÀÖ´Â ºÐµéÀº ¸¸ 80¼¼±îÁö´Â °¡´ÉÇÒ °Í °°½À´Ï´Ù.

[2015-2-7. ÀÌÁØÇà ÀÇ°ß]

À¯¸íÇÑ ±¤°íÀÎ ¹Ú¿õÇö¾¾°¡ ¸¸µç '³ªÀÌ´Â ¼ýÀÚ¿¡ ºÒ°úÇÏ´Ù'¶ó´Â copy°¡ À¯ÇàÀÎ ÀûÀÌ ÀÖ½À´Ï´Ù.

Àú´Â Á» ´Ù¸£°Ô º¾´Ï´Ù. "³ªÀÌ´Â Áß¿äÇÑ ¼ýÀÚ´Ù." Æò±ÕÁ¤µµÀÇ °Ç°­À» °¡Áø ¸¸ 89¼¼ÀÇ ¼ºÀο¡°Ô ºÐº¯ ÀáÇ÷°Ë»ç¸¦ ±ÇÇÏ´Â °ÍÀº nonsenseÀÔ´Ï´Ù. ½ÃÀÛÀÌ Àß ¸ø µÇ¾úÀ¸´Ï ÀÏÀÌ ²¿ÀÌ´Â °ÍÀÔ´Ï´Ù. ´ëÇѹα¹ Á¤ºÎ´Â ÇÏ·ç »¡¸® °Ç°­°ËÁøÀÇ age upper limit¸¦ Á¤ÇØ¾ß ÇÒ °ÍÀÔ´Ï´Ù. Expected survivalÀÌ 10³â ¹Ì¸¸¿¡¼­´Â °ËÁøÀ» ±ÇÇÏÁö ¾Ê´Â °ÍÀÌ »ó·ÊÀÔ´Ï´Ù.


[2015-4-19. ÀÌÁØÇà ÀÇ°ß]

2015³â 4¿ù 19ÀÏ ¼ÒÈ­±âÇÐȸ PG ÄÚ½º¿¡¼­ À§¾ÏȯÀÚ Áõ·Ê¿¡ ´ëÇÑ ´ÙÇÐÁ¦ Åä·ÐÀ» ÇÏ¿´½À´Ï´Ù. Àú´Â 79¼¼ ¿©ÀÚȯÀÚÀÇ À§¾Ï ESD ÈÄ ¼ö¼úÀÌ ÇÊ¿äÇÑ °á°ú°¡ ³ª¿Â Áõ·Ê¸¦ ¹ßÇ¥ÇÏ¿´½À´Ï´Ù. ÀÚ¿¬½º·´°Ô °ÇÁø³»½Ã°æ upper age limitation¿¡ ´ëÇÑ ³íÀÇ·Î ¿¬°áµÇ¾ú½À´Ï´Ù. µÎ °³ÀÇ Áß¿äÇÑ comment¸¦ µé¾ú½À´Ï´Ù.

1. ÁÂÀå´ÔÀ¸·ÎºÎÅÍ Áú¹® °â comment°¡ ÀÖ¾ú½À´Ï´Ù. "¹ßÇ¥ÀÚÀÇ ºÎ¸ð´Ô ¿¬¼¼´Â ¾î¶»°Ô µË´Ï±î?"

2. ±¹°¡¾Ï°ËÁø ÇÁ·Î±×·¥À» °³Á¤ÇÏ´Â TF¿¡ Âü¿©Çϼ̴ø ÇÑ ±³¼ö´Ô²²¼­ ¸»¾¸Çϼ̽À´Ï´Ù. "85¼¼¸¦ upper limit·Î Á¦¾ÈÇÏ¿´½À´Ï´Ù. º¸°Çº¹ÁöºÎ¿¡¼­ ÀÌ Á¦¾ÈÀ» ¹Þ¾ÆµéÀÏÁö´Â ¾ÆÁ÷ ¹ÌÁö¼öÀÔ´Ï´Ù."

µ¿¹æ¿¹ÀÇÁö±¹¿¡¼­ ÃÊ°í·ÉÀÚÀÇ °ÇÁø³»½Ã°æ Áß´Ü ½ÃÁ¡À» Á¤ÇØ¾ß ÇÑ´Ù°í ÁÖÀåÇÏ´Â ÀÏÀº ¹«Ã´ ¾î·Æ´Ù´Â °ÍÀ» ´Ù½Ã Çѹø ´À²¼½À´Ï´Ù.


[2018-4-14. Ç︮ÄÚ¹ÚÅÍÇÐȸ meet the professor session¿¡¼­ Àü¼º¿ì ±³¼ö´ÔÀÇ Áú¹®]

75¼¼ À̻󿡼­ °ËÁø ³»½Ã°æÀ» ±ÇÇÏÁö ¸»ÀÚ´Â °¡À̵å¶óÀÎÀ» ¼Ò°³ÇØ Áּ̽À´Ï´Ù. ±×·¯³ª, 75¼¼ ÀÌ»ó ³ëÀε鵵 ¸Å¿ì °Ç°­ÇÑ ºÐµéÀÌ ¸¹½À´Ï´Ù. °Ç°­ÇÑ °í·ÉÀÚ¿¡¼­ À§¾ÏÀ» ¹ß°ßÇÏ¿© Ä¡·áÇØ µå¸®´Â °ÍÀº ÀǹÌÀÖ´Â ÀÏÀ̶ó°í »ý°¢ÇÕ´Ï´Ù. ¾î¶² ÀÇ°ßÀ» °¡Áö°í °è½Ã´ÂÁö¿ä?

[2018-4-14. ÀÌÁØÇà ´äº¯]

ÁÁÀº Áú¹® °¨»çÇÕ´Ï´Ù. Íë°ú ÞçÀÇ ±¸ºÐ À̽´À̸鼭 individualizeÀÇ ¹®Á¦ÀÔ´Ï´Ù. Àü±¹¹ÎÀ» ´ë»óÀ¸·Î ¹Ý°­Á¦Àû °ËÁøÀ» pushÇϱâ À§Çؼ­´Â ÃæºÐÈ÷ ±Ù°Å°¡ ÀÖ¾î¾ß ÇÕ´Ï´Ù. µæº¸´Ù ÇØ°¡ ¸¹Àº °ÍÀ» Á¤ºÎ°¡ ±¹¹Î¿¡°Ô ±ÇÇϰųª °­Á¦ÇÏ¸é ¾ÈµÇ±â ¶§¹®ÀÔ´Ï´Ù. ±¹¹ÎÀÇ Ç÷¼¼·Î ÁøÇàµÇ´Â »ç¾÷¿¡¼­´Â ´õ´õ¿í ¸íÈ®ÇÑ ±Ù°Å°¡ ÀÖ¾î¾ß ÇÕ´Ï´Ù. 75¼¼ ÀÌ»ó Àü±¹¹ÎÀ» ´ë»óÀ¸·Î screening gastroscopy¸¦ ±ÇÇÏ´Â °ÍÀº ±Ù°Å°¡ ¾ø±â ¶§¹®¿¡ °¡À̵å¶óÀο¡¼­ ¾ð±ÞµÈ ¹Ù¿Í °°ÀÌ ´çÀå ÁߴܵǾî¾ß ¸¶¶¥ÇÑ ÀÏÀÔ´Ï´Ù.

75¼¼ ÀÌ»óÀÌ¶óµµ ÃæºÐÈ÷ °Ç°­ÇÏ°í expected survivalÀÌ 10³â ÀÌ»óÀÎ °æ¿ì´Â screening gastroscopy¸¦ ±ÇÇÒ ¼ö ÀÖ½À´Ï´Ù. À̸¦ À§Çؼ­´Â ¸Å¿ì Á¤±³ÇÑ Á¤Ã¥ÀÌ ÇÊ¿äÇϵ¥, ¿ì¸®³ª¶ó¿¡´Â ¾ÆÁ÷ À̸¦ À§ÇÑ data³ª ¹æ¹ý·ÐÀÌ È®¸³µÇ¾î ÀÖÁö ¾Ê½À´Ï´Ù.

¹Ý´ë·Î 75¼¼ ÀÌÇÏ¶óµµ °Ç°­ÇÏÁö ¾Ê°í expected survivalÀÌ 10³â ¹Ì¸¸ÀÎ °æ¿ì´Â screening gastroscopyÀÇ ¿¹¿Ü·Î »ï¾Æ¾ß ÇÕ´Ï´Ù. À̸¦ À§ÇÑ data³ª ¹æ¹ý·ÐÀÌ È®¸³µÇ¾î ÀÖÁö ¾ÊÀº °Íµµ ¸¶Âù°¡ÁöÀÔ´Ï´Ù.

Çö ½ÃÁ¡¿¡¼­´Â more and more¸¦ Ãß±¸Çϱ⿡ ¾Õ¼­ Àá½Ã ¼Óµµ¸¦ ÁÙÀÌ°í µ¥ÀÌŸ¸¦ ¸ðÀ¸¸é¼­ Á¤Ã¥À» ´Ùµë¾î¾ß ÇÒ °ÍÀÔ´Ï´Ù. Screening ¹®Á¦¸¦ Á¤Ä¡ÀûÀ¸·Î Á¢±ÙÇÏ´Â ÇöÀçÀÇ °üÇà-ÀÌ ¶ÇÇÑ ÀûÆóÀÔ´Ï´Ù-À» û»êÇØ¾ß ÇÕ´Ï´Ù. ScreeningÀº °Ç°­ ¹®Á¦ÀÌ°í ÀÇÇÐ ¹®Á¦ÀÔ´Ï´Ù. ÆÛÁÖ±â´Â °ï¶õÇÕ´Ï´Ù. 90¼¼°í 100¼¼°í ¹«Á¶°Ç °ËÁø µüÁö¸¦ º¸³»´Â °ÍÀº ±¹°¡ Æø·ÂÀ̶ó°í »ý°¢ÇÕ´Ï´Ù.

[2022-5-31] °í·É °ËÁø ÈÄ ESD ÈÄ atypia ÃßÀû°Ë»ç


[References]

1) EndoTODAY ¾Ï°ËÁø

2) [2017-8-29. Á¶¼±ÀϺ¸] ³ë³â±â¿¡ ³Ê¹«³ª ¸¹ÀÌ ÇàÇØÁö´Â °Ë»çµé (±èöÁß ±âÀÚ)

86¼¼ ³²ÀÚ°¡ ´ëÇк´¿ø ¼ÒÈ­±â³»°ú·Î ³»½Ã°æ ½Ã¼úÀ» ¹ÞÀ¸·¯ ¿Ô´Ù. µ¿³× º´¿ø¿¡¼­ ½ÃÇàÇÑ ´ëÀå³»½Ã°æ¿¡¼­ ¾ç¼º ȤÀÎ ¿ëÁ¾(Æú¸³)ÀÌ ¹ß°ßµÆ±â¿¡ ¶¼·¯ ¿Â °ÍÀÌ´Ù. Æò¼Ò¿¡ ¾Æ¹«·± Áõ»óÀÌ ¾ø¾ú´ø ±×´Â ÃÖ±Ù ±¹°¡ 5´ë¾Ï °ËÁøÀ¸·Î ½ÃÇàÇÑ ´ëº¯ ÀáÇ÷ °Ë»ç¿¡¼­ ¾ç¼ºÀÌ ³ª¿Ô´Ù. ´ëº¯¿¡ Ç͹æ¿ïÀÌ ¼¯¿© ÀÖÀ¸´Ï ´ëÀå ¼ÓÀ» µÚÁ®º¸¶ó´Â Àǹ̴Ù. ³»½Ã°æÀ» ¹Þ¾Ò°í, °Å±â¼­ 1§¯°¡ ä ¾È µÇ´Â ÀÛÀº Äá¾Ë¸¸ ÇÑ ¿ëÁ¾ÀÌ µÎ °³ ³ª¿Ô´Ù. µ¿³× º´¿ø¿¡¼­´Â ³ªÀ̵µ ÀÖ°í ÇÏ´Ï ´ëÇк´¿ø¿¡ °¡¼­ Á¦°ÅÇÏ´Â °Ô ÁÁ°Ú´Ù°í ±ÇÀ¯Çß´Ù. ¿ëÁ¾Àº ³ªÁß¿¡ ´ëÀå¾ÏÀÌ µÉ ¼ö ÀÖ°í, Ŭ¼ö·Ï ¾Ï¼¼Æ÷°¡ ÀÖÀ» È®·üÀÌ ³ô´Ù.

Æȼø ³Ñ¾î ¶§¸¶Ä§ ´ëº¯ ÀáÇ÷ °Ë»ç¸¦ ¹ÞÀº ±×°¡ À̾ ³»½Ã°æÀ¸·Î ´ëÀå¾Ï ½ÏÀ» Àß¶ó³¾ ¼ö ÀÖ°Ô µÆÀ¸´Ï ´ÙÇàÀÎ °É±î. ÀþÀº ³ªÀ̶ó¸é ¸ÂÁö¸¸, °í·ÉÀÇÇÐ °üÁ¡¿¡¼­´Â ±×·¸Áö ¾Ê´Ù. ¿ëÁ¾ Å©±â°¡ µÎ ¹è·Î ÀÚ¶ó´Â ±â°£Àº ¾î¸²Àâ¾Æ 5³âÀ¸·Î º»´Ù. 2§¯·Î ÀÚ¶õ ±×ÀÇ ¿ëÁ¾ÀÌ ´ëÀå¾ÏÀ¸·Î ÆÇÁ¤µÉ È®·üÀº 25% Á¤µµ´Ù. ÀÌ¹Ì 91¼¼°¡ µÆÀ» ¶§´Ù. Çѱ¹ÀÎÀÇ ±â´ë ¿©¸íÀ» ¾Ë·ÁÁÖ´Â »ý¸íÇ¥¿¡ µû¸£¸é, ÇöÀç 86¼¼ ³²ÀÚ¿¡°Ô ³²Àº ±â°£Àº 6³âÀÌ´Ù. ¼³»ç À̹ø¿¡ ¹ß°ßµÈ ¿ëÁ¾ÀÌ ´ëÀå¾Ï Ãʱ⿴´Ù¼Õ Ä¡´õ¶óµµ »ý¸íÀ» À§ÇùÇÒ Á¤µµ·Î ÀÚ¶ó´Â µ¥´Â ±× Á¤µµÀÇ »ó´çÇÑ ±â°£ÀÌ Èê·¯¾ß ÇÑ´Ù. ¿ëÁ¾À» Á¦°ÅÇϳª ³öµÎ³ª, ¸ÅÇÑ°¡ÁöÀÎ °æ¿ì´Ù. °á±¹ ±×´Â ¾Ö½á ´ëÀå³»½Ã°æÀ» ¹Þ¾Æ°¡¸ç ±¦ÇÑ °ÍÀ» ã¾Æ³½ ¼ÀÀÌ µÆ´Ù.

ÀÌ·± ¹®Á¦´Â °í·É»çȸ¸¦ ¸ÂÀÌÇÏ´Â ¿ì¸®¿¡°Ô ´Ù¾çÇÑ 'ºÒÆíÇÑ Áø½Ç'À» ´øÁ®ÁÖ°í ÀÖ´Ù. ¿äÁò È¿µµ °ËÁøÀ̶ó´Â ¸í¸ñÀ¸·Î, ´õ ÀßÇØ µå¸®°Ú´Ù´Â ³»½ÉÀ¸·Î, ÀÌ¿ÕÀÌ¸é ¾ÏÀ» Á¶±â ¹ß°ßÇÏÀÚ´Â ÃëÁö·Î ³ë³â±â¿¡ ³Ê¹«³ª ¸¹Àº °Ë»ç¸¦ ¹Þ°Ô ÇÏ°í Àֱ⠶§¹®ÀÌ´Ù. ¹Ì±¹ Áúº´¿¹¹æƯº°À§¿øȸ´Â ¹«Áõ»ó ³ë³â¿¡°Ô ´ëÀå¾Ï °ËÁøÀ» ±ÇÀåÇÏÁö ¾Ê´Â´Ù. 85¼¼ À̻󿡼­´Â ´ëÀå³»½Ã°æ °ËÁøÀ» ÇÏÁö ¾Ê´Â °Ô ÁöħÀÌ´Ù. 50¼¼ºÎÅÍ 75¼¼±îÁö¸¸ ÇÏ¸é µÈ´Ù. 76~85¼¼ »çÀÌ¿¡¼­´Â À§Çè ¿äÀο¡ µû¶ó ÇÒ ¼öµµ ÀÖ°í ¾È ÇÒ ¼öµµ ÀÖ´Ù.

´ëÀå¾Ï ¹ß»ýÀÌ ³ôÀº ¹Ì±¹ÀÌÁö¸¸, °í·ÉÀÚ ³»½Ã°æ °ËÁø¿¡ ½ÇÀÍÀÌ ¾ø´Ù´Â ÀÌÀ¯´Ù. ¼³»ç¸¦ ¼¼°Ô ½ÃÄÑ¾ß ÇÏ°í, ¶§·Ð ¼ö¸é ¸¶Ã븦 ÇØ¾ß ÇÏ°í, µå¹°Áö¸¸ ³»½Ã°æ µµÁß ÃâÇ÷À̳ª õ°øÀÇ ¿ì·Á¸¦ °¨¼öÇØ¾ß ÇÑ´Ù. ±× ³ªÀÌ¿¡ ±×·¸°Ô Çؼ­ ´ëÀå¾ÏÀ» ÀÏÂï ã¾Æ³½µé ¼ö¸í¿¡ ¿µÇâÀ» ¹ÌÄ¡´Â °æ¿ì°¡ Àû±â¿¡, ¾Æ¿¹ ³»½Ã°æ °ËÁøÀ» ÇÏÁö ¾Ê´Â °Ô ³´´Ù´Â ºÐ¼®ÀÌ´Ù. ¹°·Ð ÀåÃâÇ÷À̳ª ¹èº¯ Àå¾Ö°¡ »ý°Ü¼­, Áõ»óÀ» ÇØ°áÇϱâ À§ÇÑ ´ëÀå³»½Ã°æÀº ³ªÀÌ¿Í »ó°ü¾øÀÌ ¹Þ¾Æ¾ß ÇÑ´Ù.

ÇÏÁö¸¸ ¿ì¸®³ª¶ó¿¡¼­´Â ¹«Áõ»óÀÓ¿¡µµ 90¼¼¿¡ Á¾ÇÕ°ËÁøÀ» ¹ÞÀ¸¸ç ´ëÀå³»½Ã°æÀ» ¹Þ´Â À̵éÀ» ²Ï º»´Ù. º»ÀÎÀÌ ¿øÇؼ­ ¹Þ°Ú´Ù°í ÇÏ¸é ¸»¸®Áöµµ ¸øÇÑ´Ù. ±â´ë ¼ö¸í ¿î¿îÇß´Ù°¡´Â ¼·¼·ÇÏ´Ü ¼Ò¸®¸¸ µè°Ô µÈ´Ù. ÀÌ·± ºÐÀ§±â¿¡ µû¶ó ±¹°¡ ¾Ï°ËÁø¿¡¼­µµ 85¼¼¸¦ ³Ñ±ä ÀÌ¿¡°Ô ´ëÀå¾Ï °ËÁøÀ» ¹«·á·Î Áö¿øÇØÁØ´Ù.

Çѱ¹Àο¡°Ô ÈçÇÑ À§¾Ï °ËÁøµµ ¸¶Âù°¡Áö´Ù. ±¹¸³¾Ï¼¾ÅÍ À§¾Ï °ËÁø ±Ç°í¾È¿¡ µû¸£¸é, 40¼¼ºÎÅÍ´Â Áõ»óÀÌ ¾ø´õ¶óµµ 2³â¸¶´Ù À§¾Ï °ËÁøÀ» ³»½Ã°æÀ¸·Î ¹Þ´Â °Ô ÁÁ´Ù. ±×·¯´Ù 75¼¼ºÎÅÍ 84¼¼¿¡´Â ½ÇÀÍÀ» µûÁ®º¸°í ÇÏ°í, 85¼¼ À̻󿡼­´Â ¾Æ¿¹ À§¾Ï °ËÁøÀ» ±Ç°íÇÏÁö ¾Ê´Â´Ù. ±× ³ªÀÌ´ë¿¡¼­´Â À§¾Ï °ËÁøÀ» ¹ÞÀº »ç¶÷ÀÌ ¹ÞÁö ¾ÊÀº »ç¶÷º¸´Ù »ç¸Á·üÀÌ ´õ ³ô±â ¶§¹®ÀÌ´Ù. ½Ã¼ú·Î ÀÎÇÑ ÈÄÀ¯ÁõÀÌ ´õ Å©´Ù´Â Àǹ̴Ù. ÃÊ°í·ÉÀÚ¿¡°Ô Á¶±â À§¾Ï ã¾Æ³½´ä½Ã°í ³»½Ã°æÀ» Çϸé, ±Ü¾î ºÎ½º·³ ¸¸µå´Â ²ÃÀ̶ó´Â ¾ê±â´Ù.

±×·³¿¡µµ ±¹°¡¾Ï°ËÁø»ç¾÷¿¡¼­´Â ³ªÀÌ Á¦ÇÑ ¾øÀÌ ÃÊ°í·ÉÀÚ¿¡°Ôµµ À§¾Ï ¹«»ó °ËÁø ¾È³»¹®À» º¸³½´Ù. ±×µéÀ» Á¦¿ÜÇϸé Àú°£ÀÇ »çÁ¤Àº ¿Ü¸éµÈ ä "³ªÀÌ µé¾ú´Ù°í º¹Áö ÇýÅÃÀ» »©´Â °Å³Ä. ¼­¿îÇÏ´Ù"´Â Ç×ÀÇ°¡ ´çÀå ³ª¿Ã Å×°í, À̸¦ °¨´çÇÒ ÀÚ½ÅÀÌ ¾øÀ¸´Ï ÃÊ°í·ÉÀÚ À§¾Ï °ËÁøÀº Áö¼ÓÇÏ°í ÀÖ´Ù. È¿½ÉÀÌ µÇ·¹ ºÒÈ¿°¡ µÉ ¼ö ÀÖ°í, ºÎÁö·±ÇÔÀÌ ¿Ü·Á ±×¸©µÊÀ¸·Î À̾îÁú ¼ö Àִµ¥µµ ¸»ÀÌ´Ù.

³ªÀÌ´Â ¼ýÀÚ¿¡ ºÒ°úÇÏ´Ù´Â ¸»À» ÈçÈ÷ ÇÏÁö¸¸, ³ªÀÌ´Â ³ªÀÌ´Ù. °í·ÉÀÚ °ËÁøÀº ÆÇÀÌ ´Þ¶ó¾ß ÇÑ´Ù. 50´ë¿Í 60´ëó·³ ÇÑâ º´ÀÌ »ý±æ ½Ã±â¿¡´Â Á¶±â ¹ß°ßÀÌ À¯È¿ÇÏ´Ù. ÇÏÁö¸¸ ³ë³âÃþ¿¡¼­´Â Áõ»óÀÌ ¾ø´Â »óÅ¿¡¼­ º´À» »õ·Î ã¾Æµµ Àڱ⠼ö¸í¿¡ º¯È­¸¦ ÁÙ °ÍÀÌ ¾Æ´Ï°Å³ª, ã¾Æ³½µé Ä¡·á¸¦ °¨´çÇÒ ¸öÀÌ ¾Æ´Ï¸é Á¾ÇÕ°ËÁøÀ» ÇÒ ÀÌÀ¯°¡ ¾ø´Ù. Àλý Á¾¹ÝÀº Áúº´ Ä¡·áº¸´Ù ½Åü ±â´É À¯Áö¿Í ȸº¹ÀÌ ¿ì¼±ÀÌ´Ù. ¸ö¼Ó¿¡ ¾ÏÀÌ À־ ¿ÏÄ¡µÉ °ÍÀÌ ¾Æ´Ï¶ó¸é ¾Ï Ä¡·á¿¡ Èû »©±âº¸´Ù, ±Ù°ñ°Ý °­È­¿¡ Èû¾²´Â °Ô ³´´Ù. ±×°ÍÀÌ »îÀÇ ÁúÀ» ´õ ÁÁ°Ô ÇÏ°í ³²Àº ÀλýÀ» dz¿ä·Ó°Ô ÇÑ´Ù. ¾Ï °ËÁøº¸´Ù ÀÎÁö±â´É, º¸Çà ±Ù·Â, ³«»ó À§Çè, ¹è´¢ µî ÀÏ»ó¿¡ ¿µÇâÀ» ÁÙ ½Åü ±â´É Æò°¡¸¦ ¹Þ°í °³¼±ÇÏ´Â °Ô ÈξÀ ³´´Ù. °í·É Àå¼ö »çȸ¿¡¼­´Â Àß ¹öƼ´Â ³»±¸·ÂÀÌ ÃÖ°í´Ù.

3) [2024-1-10. ¿±ÇÕ] ´Ä¾î°¡´Â Çѱ¹. 20´ë ÀÌ»ó Àα¸, 20´ëº¸´Ù ¸¹¾ÆÁ³´Ù



© ÀÏ¿ø³»½Ã°æ±³½Ç ¹Ù¸¥³»½Ã°æ¿¬±¸¼Ò ÀÌÁØÇà. EndoTODAY Endoscopy Learning Center. Lee Jun Haeng.